Max Masucci
Stock Analyst at TD Cowen
(0.20)
# 4,202
Out of 4,876 analysts
23
Total ratings
16%
Success rate
-31.44%
Average return
Main Sectors:
Stocks Rated by Max Masucci
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BRKR Bruker | Maintains: Hold | $74 → $72 | $41.80 | +72.25% | 1 | Aug 7, 2024 | |
| BLFS BioLife Solutions | Maintains: Outperform | $29 → $25 | $21.50 | +16.28% | 1 | Aug 9, 2023 | |
| GH Guardant Health | Maintains: Outperform | $70 → $53 | $50.86 | +4.21% | 1 | Feb 24, 2023 | |
| HOLX Hologic | Maintains: Outperform | $86 → $95 | $65.01 | +46.13% | 2 | Feb 2, 2023 | |
| QTRX Quanterix | Downgrades: Market Perform | $38 → $18 | $6.65 | +170.68% | 2 | Aug 9, 2022 | |
| BDSX Biodesix | Initiates: Outperform | n/a | $0.25 | - | 2 | Apr 20, 2022 | |
| EVO Evotec SE | Initiates: Outperform | n/a | $4.18 | - | 1 | Nov 29, 2021 | |
| NAUT Nautilus Biotechnology | Initiates: Outperform | n/a | $0.69 | - | 1 | Nov 2, 2021 | |
| MXCT MaxCyte | Initiates: Outperform | n/a | $2.20 | - | 1 | Aug 24, 2021 | |
| CTKB Cytek Biosciences | Initiates: Outperform | n/a | $3.54 | - | 1 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.60 | - | 1 | Aug 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.11 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.24 | +1,916.13% | 1 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $460 → $470 | $94.79 | +395.83% | 4 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $6.99 | +257.91% | 1 | Apr 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $145 | $53.65 | +170.27% | 2 | Oct 28, 2020 |
Bruker
Aug 7, 2024
Maintains: Hold
Price Target: $74 → $72
Current: $41.80
Upside: +72.25%
BioLife Solutions
Aug 9, 2023
Maintains: Outperform
Price Target: $29 → $25
Current: $21.50
Upside: +16.28%
Guardant Health
Feb 24, 2023
Maintains: Outperform
Price Target: $70 → $53
Current: $50.86
Upside: +4.21%
Hologic
Feb 2, 2023
Maintains: Outperform
Price Target: $86 → $95
Current: $65.01
Upside: +46.13%
Quanterix
Aug 9, 2022
Downgrades: Market Perform
Price Target: $38 → $18
Current: $6.65
Upside: +170.68%
Biodesix
Apr 20, 2022
Initiates: Outperform
Price Target: n/a
Current: $0.25
Upside: -
Evotec SE
Nov 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.18
Upside: -
Nautilus Biotechnology
Nov 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.69
Upside: -
MaxCyte
Aug 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.20
Upside: -
Cytek Biosciences
Aug 17, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.54
Upside: -
Aug 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.60
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.11
Upside: -
May 11, 2021
Initiates: Buy
Price Target: $25
Current: $1.24
Upside: +1,916.13%
Apr 28, 2021
Maintains: Buy
Price Target: $460 → $470
Current: $94.79
Upside: +395.83%
Apr 15, 2021
Initiates: Buy
Price Target: $25
Current: $6.99
Upside: +257.91%
Oct 28, 2020
Maintains: Buy
Price Target: $120 → $145
Current: $53.65
Upside: +170.27%